Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Director departure Notes underwriting agrmnt
|
Histogen Inc. (CNAT)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/12/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
10/04/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
10/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement Interactive Data |
09/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
08/15/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
07/05/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/11/2023 |
8-K
| Quarterly results |
05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/28/2023 |
4/A
| Reyes Joyce (See Remarks) has filed a Form 4 on Histogen Inc.
Txns:
| Granted 47,417 options to buy
@ $0.95, valued at
$45k
Granted 16,659 options to buy
@ $0.95, valued at
$15.8k
Disposed/sold 1,200 options to buy
@ $0 Disposed/sold 4,452 options to buy
@ $0 Disposed/sold 7,833 options to buy
@ $0 |
|
04/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
03/14/2023 |
4
| Reyes Joyce (See Remarks) has filed a Form 4 on Histogen Inc.
Txns:
| Granted 47,417 options to buy
@ $0.95, valued at
$45k
Granted 16,659 options to buy
@ $0.95, valued at
$15.8k
Disposed/sold 1,200 options to buy
@ $0 Disposed/sold 7,833 options to buy
@ $0 |
|
03/14/2023 |
4
| Knudson Susan A. (COO and CFO) has filed a Form 4 on Histogen Inc.
Txns:
| Granted 79,027 options to buy
@ $0.95, valued at
$75.1k
Granted 27,766 options to buy
@ $0.95, valued at
$26.4k
Disposed/sold 6,206 options to buy
@ $0 Disposed/sold 5,600 options to buy
@ $0 Disposed/sold 8,490 options to buy
@ $0 |
|
03/14/2023 |
4
| Mento Steven J (President and CEO) has filed a Form 4 on Histogen Inc.
Txns:
| Granted 158,055 options to buy
@ $0.95, valued at
$150.2k
Granted 55,532 options to buy
@ $0.95, valued at
$52.8k
Disposed/sold 18,892 options to buy
@ $0 Disposed/sold 7,582 options to buy
@ $0 |
|
03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/09/2023 |
8-K
| Quarterly results |
02/27/2023 |
4
| Spada Alfred P. (See Remarks) has filed a Form 4 on Histogen Inc.
Txns:
| Granted 106,793 options to buy
@ $1.041, valued at
$111.2k
|
|
02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 5% stake in Histogen Inc. |
02/08/2023 |
SC 13G/A
| INTRACOASTAL CAPITAL, LLC reports a 5.3% stake in Histogen Inc. |
02/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
01/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
|
"EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT is entered into as of February 1, 2023 , by and between Histogen Inc., a Delaware corporation , and Alfred P. Spada Ph.D. . RECITALS WHEREAS, Employer wishes to engage Executive as Executive Vice President and Chief Scientific Officer on the terms and conditions hereinafter set forth. AGREEMENT NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements set forth herein, Executive and Employer agree as follows: 1. Employment Term. The term of this Agreement shall commence on the Effective Date and will continue until terminated as provided in Section 7 below. 2. Scope of Employment. a. Position and Duties. Executive shall serve as Company’s CSO. Executive agrees that during the Employme...",
"Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, January 3, 2023 -- Histogen Inc. , a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer. “We are very excited about Dr. Spada joining our management team. Dr. Spada is a world expert in both the biology of apoptosis and the chemistry of designing potent caspase inhibitors,” sa..." |
|
12/02/2022 |
8-K
| Quarterly results |
11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/10/2022 |
8-K
| Quarterly results |
11/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/11/2022 |
8-K
| Quarterly results |
08/04/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
08/03/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
07/28/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
07/12/2022 |
8-K
| Quarterly results |
06/30/2022 |
8-K
| Quarterly results |
|
|
|